Please assess the completion status of the following clinical trial:

Trial Title: Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the Investigator believes that they can and will comply with the requirements of the protocol~* Subjects who have no evidence of exposition to BCG as demonstrated by a ELISPOT PPD assay along with no history of BCG vaccination and no BCG scar~* A male or female between, and including, 18 and 45 years of age at the time of the vaccination.~* Written informed consent obtained from the subject prior to any study procedure.~* If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception~* Clinically acceptable laboratory values for blood tests.~* Seronegative for human immunodeficiency virus 1 and -2 (HIV-1/2) antibodies, p24 antigen, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibodies.~* No evidence of pulmonary pathology as confirmed by chest X-ray.~* No history of extrapulmonary TB.~* No history of previous contact with M. tuberculosis (latent tuberculosis) as demonstrated by a negative ELISPOT Tb (ESAT-6, CFP10) assay.~Exclusion Criteria:~* History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunisations (any vaccine).~* History of allergic disease or reactions~* History of previous administration of experimental Mycobacterium tuberculosis vaccines.~* Use of any investigational or non-registered product (drug or vaccine) in another experimental protocol other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period.~* Any chronic drug therapy to be continued during the study period.~* Chronic administration of immunosuppressors or other immune-modifying drugs.~* Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the vaccination, or planned administrations during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (including HIV) based on medical history and physical examination.~* Any condition or history of any acute or chronic illness or medication which, in the opinion of the Investigator, may interfere with the evaluation of the study objectives.~* A family history of congenital or hereditary immunodeficiency.~* A stay of more than 2 months in a highly endemic area (e.g. Eastern Europe (Romania, Bulgaria) and low-income countries) within 6 months prior to the screening visit or travel of more than 2 months foreseen in an area of high endemicity after the enrolment into the study.~* History of any neurologic disorders or seizures.~* History of chronic alcohol consumption and/or drug abuse.~* Major congenital defects.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- MTBVAC group 1 (Type: EXPERIMENTAL): Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
- MTBVAC Group 2 (Type: EXPERIMENTAL): Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
- MTBVAC Group 3 (Type: EXPERIMENTAL): Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
- BCG Control Group (Type: ACTIVE_COMPARATOR): Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete